Optimizing treatment outcomeswith regorafenib: Personalized dosing and other strategies to support patient care

Oncologist

Volumn 19, Issue 6, 2014, Pages 669-680

  Grothey, Axel ^a   George, Suzanne ^b   van Cutsem, Eric ^c   Blay, Jean Yves ^d   Sobrero, Alberto ^e   Demetri, George D ^b  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d CENTRE LÉON BÉRARD   (France)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

Adverse events; Dose optimization; Hand foot skin reaction; Multikinase inhibitor; Regorafenib; Supportive management

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AXITINIB; BEVACIZUMAB; BILIRUBIN; CABOZANTINIB; CAPECITABINE; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; LACTATE DEHYDROGENASE; LIVER ENZYME; MAGNESIUM SILICATE; PAZOPANIB; REGORAFENIB; SORAFENIB; SUNITINIB; TRIACYLGLYCEROL LIPASE; ZINC OXIDE; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLISTER; BLOOD PRESSURE; CALLUS; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COLORECTAL CARCINOMA; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEVER; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEADACHE; HOARSENESS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERURICEMIA; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CANCER; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; MYALGIA; NAUSEA; ORAL MUCOSITIS; OVERALL SURVIVAL; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RASH; SENSORY NEUROPATHY; SKIN REDNESS; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; XEROSTOMIA; DISEASE FREE SURVIVAL; DOSE CALCULATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL STROMAL TUMORS; PATHOLOGY; PATIENT; PERSONALIZED MEDICINE;

DISEASE-FREE SURVIVAL; DRUG DOSAGE CALCULATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL STROMAL TUMORS; HAND-FOOT SYNDROME; HUMANS; INDIVIDUALIZED MEDICINE; PATIENTS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; TREATMENT OUTCOME;

EID: 84901937880     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0059     Document Type: Article

References (31)

1. Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinaseswithpotent preclinicalantitumor activity. Int J Cancer 2011;129:245-255
2. Bolondi L, Tak WY, Gasbarrini A et al. 6576 POSTER phase II safety study of the oral multikinase inhibitor regorafenib (BAY 73-4506) as second-line therapy in patients with hepatocellular carcinoma. Eur J Cancer 2011;47(suppl 1):S464
3. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302
4. Eisen T, Joensuu H, Nathan PD et al. Regorafenib for patients with previously untreatedmetastatic or unresectable renal-cell carcinoma: A single-group phase 2 trial. Lancet Oncol 2012;13:1055-1062
5. Furuse J, Sasaki Y, Okusaka T et al. 1236 POSTER phase I study to assess the safety, tolerability and pharmacokinetics of themultikinase inhibitor regorafenib (BAY 73-4506) in Japanese patients with advanced solid tumours. Eur J Cancer 2011;47(suppl 1):S155
6. George S, Wang Q, Heinrich MC et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial. J Clin Oncol 2012;30:2401-2407
7. Grothey A, van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 2013;381:303-312
8. Mross K, Frost A, Steinbild S et al. Aphase I doseescalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012;18:2658-2667
9. Strumberg D, Scheulen ME, Schultheis B et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: A phase I study. Br J Cancer 2012;106:1722-1727
10. Belum VR, Wu S, Lacouture ME. Risk of handfoot skin reaction with the novel multikinase inhibitor regorafenib: A meta-analysis. Invest New Drugs 2013;31:1078-1086
11. Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: Experience in breast cancer. The Oncologist 2011;16:1508-1519
12. Grothey A, Sobrero AF, Siena S et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. J Clin Oncol 2013;31:3637a.
13. Chu D, Lacouture ME, Fillos T et al. Risk of handfoot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 2008;47:176-186
14. Chu D, Lacouture ME, Weiner E et al. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: A meta-analysis. Clin Genitourin Cancer 2009;7:11-19
15. Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-1961
16. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. The Oncologist 2008;13:1001-1011
17. Bracarda S, Ruggeri EM, Monti M et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the SorafenibWorking Group. Crit Rev Oncol Hematol 2012;82:378-386
18. Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: Viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 2011;9:13-23
19. Iijima M, Fukino K, Adachi M et al. Sorafenibassociated hand-foot syndrome in Japanese patients. J Dermatol 2011;38:261-266
20. La Vine DB, Coleman TA, Davis CH et al. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol 2010;33:217-220
21. Poprach A, Pavlik T, Melichar B et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: A national registry-based study. Ann Oncol 2012;23:3137-3143
22. O'Dwyer M, Atallah E. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Semin Hematol 2009;46(suppl 3):S16-S21
23. Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia. J Clin Oncol 2008; 26:3204-3212
24. Nardone B, Hensley JR, Kulik L et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. JDrugs Dermatol 2012; 11:e61-e65
25. Anderson R, Jatoi A, Robert C et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). TheOncologist 2009;14:291-302
26. Lacouture ME, Maitland ML, Segaert S et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010;18: 509-522
27. Ren Z, Zhu K, Kang H et al. A randomized controlledphase II studyof the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. J Clin Oncol 2012;30:4008a.
28. Choueiri TK, Mayer EL, Je Y et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011;29:632-638
29. Schutz FA, Je Y, Azzi GR et al. Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus ondifferentsubgroup outcomes. Ann Oncol 2011;22:1404-1412
30. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010;106:21-34
31. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-664.